Research graph
References from Targeting the Chromatin-Modifying Enzyme, KDM5C, Enhances AKT Inhibition Response in ER+ Breast Cancer. Local targets link to admitted publications; unresolved targets remain external evidence.
Overcoming endocrine resistance in breast cancer
10.1016/j.ccell.2020.03.009 · 2020 · External reference
Genomic characterization of metastatic breast cancers
10.1038/s41586-019-1056-z · 2019 · External reference
Preclinical pharmacology of AZD5363, an inhibitor of AKT: pharmacodynamics, antitumor activity, and correlation of monotherapy activity with genetic background
10.1158/1535-7163.mct-11-0824-t · 2012 · External reference
Comprehensive molecular portraits of human breast tumours
10.1038/nature11412 · 2012 · External reference
Landscape of phosphatidylinositol-3-kinase pathway alterations across 19 784 diverse solid tumors
10.1001/jamaoncol.2016.0891 · 2016 · External reference
The somatic mutation profiles of 2,433 breast cancers refines their genomic and transcriptomic landscapes
10.1038/ncomms11479 · 2016 · External reference
AKT/PKB signaling: navigating the network
10.1016/j.cell.2017.04.001 · 2017 · External reference
Endocrine and targeted therapy for hormone receptor-positive, human epidermal growth factor receptor 2-negative metastatic breast cancer-capivasertib-fulvestrant: ASCO rapid recommendation update
10.1200/jco.24.00248 · 2024 · External reference
6th and 7th International consensus guidelines for the management of advanced breast cancer (ABC guidelines 6 and 7)
10.1016/j.breast.2024.103756 · 2024 · External reference
Capivasertib in hormone receptor-positive advanced breast cancer
10.1056/nejmoa2214131 · 2023 · External reference
Alpelisib for PIK3CA-mutated, hormone receptor-positive advanced breast cancer
10.1056/nejmoa1813904 · 2019 · External reference
Overall survival with inavolisib in PIK3CA-mutated advanced breast cancer
10.1056/nejmoa2501796 · 2025 · External reference
Resistance to targeted inhibitors of the PI3K/AKT/mTOR pathway in advanced oestrogen-receptor-positive breast cancer
10.3390/cancers16122259 · 2024 · External reference
AKT-mTORC1 reactivation is the dominant resistance driver for PI3Kbeta/AKT inhibitors in PTEN-null breast cancer and can be overcome by combining with Mcl-1 inhibitors
10.1038/s41388-022-02482-9 · 2022 · External reference
Alterations in PTEN and ESR1 promote clinical resistance to alpelisib plus aromatase inhibitors
10.1038/s43018-020-0047-1 · 2020 · External reference
Metabolic imaging detects resistance to PI3Kalpha inhibition mediated by persistent FOXM1 expression in ER(+) breast cancer
10.1016/j.ccell.2020.08.016 · 2020 · External reference
The interplay between FOXO3 and FOXM1 influences sensitivity to AKT inhibition in PIK3CA and PIK3CA/PTEN altered estrogen receptor positive breast cancer
10.1038/s41523-025-00752-9 · 2025 · External reference
Epigenetic silencing mediated through activated PI3K/AKT signaling in breast cancer
10.1158/0008-5472.can-10-3573 · 2011 · External reference
PI3K pathway regulates ER-dependent transcription in breast cancer through the epigenetic regulator KMT2D
10.1126/science.aah6893 · 2017 · External reference
A CRISPR dropout screen identifies genetic vulnerabilities and therapeutic targets in acute myeloid leukemia
10.1016/j.celrep.2016.09.079 · 2016 · External reference
Genome-wide recessive genetic screening in mammalian cells with a lentiviral CRISPR-guide RNA library
10.1038/nbt.2800 · 2014 · External reference
MAGeCK enables robust identification of essential genes from genome-scale CRISPR/Cas9 knockout screens
10.1186/s13059-014-0554-4 · 2014 · External reference
BAGEL: a computational framework for identifying essential genes from pooled library screens
10.1186/s12859-016-1015-8 · 2016 · External reference
Drug-gene interaction screens coupled to tumor data analyses identify the most clinically relevant cancer vulnerabilities driving sensitivity to PARP inhibition
10.1158/2767-9764.crc-22-0119 · 2022 · External reference
Measuring error rates in genomic perturbation screens: gold standards for human functional genomics
10.15252/msb.20145216 · 2014 · External reference
Prioritization of cancer therapeutic targets using CRISPR-Cas9 screens
10.1038/s41586-019-1103-9 · 2019 · External reference
ROCR: visualizing classifier performance in R
10.1093/bioinformatics/bti623 · 2005 · External reference
Discovery of 4-amino-N-[(1S)-1-(4-chlorophenyl)-3-hydroxypropyl]-1-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)piperidine-4-carboxamide (AZD5363), an orally bioavailable, potent inhibitor of Akt kinases
10.1021/jm301762v · 2013 · External reference
KDM5 histone demethylases repress immune response via suppression of STING
10.1371/journal.pbio.2006134 · 2018 · External reference
Lysine demethylase 5A is required for MYC driven transcription in multiple myeloma
10.1158/2643-3230.bcd-20-0108 · 2021 · External reference
Discovery of a highly potent, selective, orally bioavailable inhibitor of KAT6A/B histone acetyltransferases with efficacy against KAT6A-high ER+ breast cancer
10.1016/j.chembiol.2023.07.005 · 2023 · External reference
The ATR inhibitor ceralasertib potentiates cancer checkpoint immunotherapy by regulating the tumor microenvironment
10.1038/s41467-024-45996-4 · 2024 · External reference
The Molecular Signatures Database (MSigDB) hallmark gene set collection
10.1016/j.cels.2015.12.004 · 2015 · External reference
Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles
10.1073/pnas.0506580102 · 2005 · External reference
ChIPseeker: an R/Bioconductor package for ChIP peak annotation, comparison and visualization
10.1093/bioinformatics/btv145 · 2015 · External reference
clusterProfiler 4.0: a universal enrichment tool for interpreting omics data
2021 · External reference
EnrichedHeatmap: an R/Bioconductor package for comprehensive visualization of genomic signal associations
10.1186/s12864-018-4625-x · 2018 · External reference
methylKit: a comprehensive R package for the analysis of genome-wide DNA methylation profiles
10.1186/gb-2012-13-10-r87 · 2012 · External reference
Lead optimization of a pyrazolo[1,5-a]pyrimidin-7(4H)-one scaffold to identify potent, selective and orally bioavailable KDM5 inhibitors suitable for in vivo biological studies
10.1016/j.bmcl.2016.06.078 · 2016 · External reference
Inhibition of lysine acetyltransferase KAT6 in ER+HER2− metastatic breast cancer: a phase 1 trial
10.1038/s41591-024-03060-0 · 2024 · External reference
The dual function of KDM5C in both gene transcriptional activation and repression promotes breast cancer cell growth and tumorigenesis
10.1002/advs.202004635 · 2021 · External reference
ESR1 mutation as an emerging clinical biomarker in metastatic hormone receptor-positive breast cancer
10.1186/s13058-021-01462-3 · 2021 · External reference
The genetic landscape and clonal evolution of breast cancer resistance to palbociclib plus fulvestrant in the PALOMA-3 trial
10.1158/2159-8290.cd-18-0264 · 2018 · External reference
The next-generation oral selective estrogen receptor degrader camizestrant (AZD9833) suppresses ER+ breast cancer growth and overcomes endocrine and CDK4/6 inhibitor resistance
10.1158/0008-5472.can-23-0694 · 2023 · External reference
Simple combinations of lineage-determining transcription factors prime cis-regulatory elements required for macrophage and B cell identities
10.1016/j.molcel.2010.05.004 · 2010 · External reference
FOXM1 is a transcriptional target of ERalpha and has a critical role in breast cancer endocrine sensitivity and resistance
10.1038/onc.2010.47 · 2010 · External reference
H3K4me3 regulates RNA polymerase II promoter-proximal pause-release
10.1038/s41586-023-05780-8 · 2023 · External reference
Integrator loss leads to dsRNA formation that triggers the integrated stress response
10.1016/j.cell.2025.03.025 · 2025 · External reference
Genomic alterations in PIK3CA-mutated breast cancer result in mTORC1 activation and limit the sensitivity to PI3Kalpha inhibitors
10.1158/0008-5472.can-20-3232 · 2021 · External reference
Methylation of the chromatin modifier KMT2D by SMYD2 contributes to therapeutic response in hormone-dependent breast cancer
10.1016/j.celrep.2024.114174 · 2024 · External reference
KDM5 histone demethylase activity links cellular transcriptomic heterogeneity to therapeutic resistance
10.1016/j.ccell.2019.01.012 · 2019 · External reference
AKT and EZH2 inhibitors kill TNBCs by hijacking mechanisms of involution
10.1038/s41586-024-08031-6 · 2024 · External reference
Chromosome region 8p11-p21: refined mapping and molecular alterations in breast cancer
10.1002/(sici)1098-2264(199807)22:3<186::aid-gcc4>3.0.co;2-s · 1998 · External reference
Genomic characterization of genes encoding histone acetylation modulator proteins identifies therapeutic targets for cancer treatment
10.1038/s41467-019-08554-x · 2019 · External reference
KAT6A, a chromatin modifier from the 8p11-p12 amplicon is a candidate oncogene in luminal breast cancer
10.1016/j.neo.2014.07.007 · 2014 · External reference
Inhibitors of histone acetyltransferases KAT6A/B induce senescence and arrest tumour growth
10.1038/s41586-018-0387-5 · 2018 · External reference
